Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2024 | Risk factors for immune-related adverse events in early-stage breast cancer

Alexis LeVee • 12 Dec 2024
SABCS 2024
Breast Cancer
KEYNOTE-522

Alexis LeVee, MD, City of Hope, Duarte, CA, comments on the incidence and predictors of immune-related adverse events (irAE) in patients with early-stage breast cancer treated with immune checkpoint inhibitors. Findings from a cohort of patients reveal that a majority experienced irAE, which is higher than the reported rate in the KEYNOTE-522 trial (NCT03036488). Older age and comorbidities such as chronic kidney disease were also risk factors for severe irAE. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Alexis LeVee

Exploring Anti-RANKL therapy with checkpoint inhibitors in breast cancer
1:20
Exploring Anti-RANKL therapy with checkpoint inhibitors in breast cancer
Alexis LeVee • 12 Dec 2024
Denosumab increases irAE in patients with breast cancer treated with pembrolizumab
1:11
Denosumab increases irAE in patients with breast cancer treated with pembrolizumab
Alexis LeVee • 12 Dec 2024
Using gut microbiota to enhance immunotherapy for breast cancer
0:58
Using gut microbiota to enhance immunotherapy for breast cancer
Alexis LeVee • 2 Jun 2024
Palbociclib, pembrolizumab, and endocrine therapy in HR+/HER2- breast cancer
1:10
Palbociclib, pembrolizumab, and endocrine therapy in HR+/HER2- breast cancer
Alexis LeVee • 2 Jun 2024

Related Videos

Stress and depression linked to tumor transcriptional signatures in breast cancer
1:21
Stress and depression linked to tumor transcriptional signatures in breast cancer
Shipra Gandhi • 31 May 2026
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
1:13
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
Shipra Gandhi • 31 May 2026
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
1:34
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
Shipra Gandhi • 1 Jun 2026
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
0:49
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
Shipra Gandhi • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals